Induction Immunosuppressive Therapy in the Elderly Kidney Transplant Recipient in the United States: "SummaryBackground and objectives
The choice of induction agent in the elderly kidney transplant recipient is unclear.
Design, setting, participants, & measurements
The risks of rejection at 1 year, functional graft loss, and death by induction agent (IL2 receptor antibodies [IL2RA], alemtuzumab, and rabbit antithymocyte globulin [rATG]) were compared among five groups of elderly (≥60 years) deceased-donor kidney transplant recipients on the basis of recipient risk and donor risk using United Network of Organ Sharing data from 2003 to 2008.
Showing posts with label Recipients. Show all posts
Showing posts with label Recipients. Show all posts
Subscribe to:
Posts (Atom)